PMID- 16174150
OWN - NLM
STAT- MEDLINE
DCOM- 20051115
LR  - 20161124
IS  - 1075-122X (Print)
IS  - 1075-122X (Linking)
VI  - 11
IP  - 5
DP  - 2005 Sep-Oct
TI  - Diagnosis of complete response to neoadjuvant chemotherapy using diagnostic 
      imaging in primary breast cancer patients.
PG  - 311-6
AB  - Advances in the therapeutic agents used for neoadjuvant chemotherapy (NAC) have 
      recently achieved higher response rates and induced a greater number of 
      pathologic complete responses (pCR) than ever before. The aim of this study is 
      the diagnosis of pCR after NAC by diagnostic imaging of clinical complete 
      response (cCR) patients. This study included 35 breast cancer patients who 
      demonstrated cCR after receiving NAC with a combination of anthracycline and 
      taxane from May 1998 to August 2003. Surgical treatment included 
      breast-conserving therapy followed by radiotherapy or mastectomy. The identity of 
      post-NAC lesions as either a complete response (CR) or partial response (PR) were 
      made by mammography, ultrasonography, and contrast-enhanced computed tomography 
      (CT). Among the 35 patients, 11 achieved pCR, including the disappearance of both 
      invasive and intraductal components. Of the patients achieving pCR, eight were 
      defined as CR and three were determined to be PR by CT. There was a significant 
      relationship between the pCR and the determination of CR by CT. The determination 
      of CR by ultrasonography was indicative of the disappearance of pathologic 
      invasive components. While mammography appeared to reflect the observed 
      histologic results, we did not observe any statistical differences. A subset of 
      cases exhibited discrepancies between the imaging and pathologic results, likely 
      due to the replacement of destroyed tumor cells by fibrosis and granulomatous 
      tissue. The evaluation of CR by CT was significantly indicative of pCR. The 
      positive predictive value, however, was not large enough to avoid surgical 
      treatment. Further studies will be needed to establish a diagnosis of pCR.
FAU - Kanazawa, Takashi
AU  - Kanazawa T
AD  - Division of Surgical Oncology, National Cancer Center Hospital, Tokyo, Japan.
FAU - Akashi-Tanaka, Sadako
AU  - Akashi-Tanaka S
FAU - Iwamoto, Eriko
AU  - Iwamoto E
FAU - Takasugi, Miyuki
AU  - Takasugi M
FAU - Shien, Tadahiko
AU  - Shien T
FAU - Kinoshita, Takayuki
AU  - Kinoshita T
FAU - Miyakawa, Kunihisa
AU  - Miyakawa K
FAU - Shimizu, Chikako
AU  - Shimizu C
FAU - Ando, Masashi
AU  - Ando M
FAU - Katsumata, Noriyuki
AU  - Katsumata N
FAU - Fujiwara, Yasuhiro
AU  - Fujiwara Y
FAU - Fukutomi, Takashi
AU  - Fukutomi T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Breast J
JT  - The breast journal
JID - 9505539
RN  - 0 (Anthracyclines)
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (Taxoids)
RN  - 1605-68-1 (taxane)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Anthracyclines/therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biopsy, Needle
MH  - Breast Neoplasms/*diagnosis/*drug therapy/mortality/surgery
MH  - Bridged-Ring Compounds/therapeutic use
MH  - Chi-Square Distribution
MH  - Cohort Studies
MH  - Diagnostic Imaging/*methods
MH  - Dose-Response Relationship, Drug
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - Magnetic Resonance Imaging/methods
MH  - Mammography/methods
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Neoplasm Staging
MH  - Probability
MH  - Prognosis
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Survival Analysis
MH  - Taxoids/therapeutic use
MH  - Tomography, X-Ray Computed/methods
MH  - Treatment Outcome
EDAT- 2005/09/22 09:00
MHDA- 2005/11/16 09:00
CRDT- 2005/09/22 09:00
PHST- 2005/09/22 09:00 [pubmed]
PHST- 2005/11/16 09:00 [medline]
PHST- 2005/09/22 09:00 [entrez]
AID - TBJ00003 [pii]
AID - 10.1111/j.1075-122X.2005.00003.x [doi]
PST - ppublish
SO  - Breast J. 2005 Sep-Oct;11(5):311-6. doi: 10.1111/j.1075-122X.2005.00003.x.